Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
Our COVID-19 Efforts
The Road to a Vaccine
About J&J
Our Credo
Our Leadership Team
Diversity, Equity & Inclusion
Veterans, Military & Military Families
Innovation at J&J
J&J Health and Wellness Solutions
ESG Policies & Positions
Code of Business Conduct
Corporate Reports
Products
Consumer Health Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2019 Janssen Transparency Report
2019 Health for Humanity Report
ESG Policies & Positions
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Sustainability Reporting
Follow Us
Facebook
Instagram
LinkedIn
Twitter
YouTube
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Czech Republic
Ecuador
Germany
India
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
United States
Uruguay
Venezuela
Share
Investor Information
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Learn More
Listen to Webcast: 39
th
Annual J.P. Morgan Healthcare Conference
Listen to Fireside Chat: Cowen and Janssen Discuss Eye Disease Portfolio
Listen to Webcast: 2020 Medical Devices Update
NYSE: JNJ
$163.55
$1.82 (
1.130
%)
Day High
$165.16
Day Low
$161.87
Volume
8,137,018
Last Updated:
1/22/2021 04.10 PM
Latest News Releases
Our Company
January 15, 2021
DARZALEX
FASPRO
®
(daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
Our Company
December 18, 2020
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
Our Company
December 14, 2020
Johnson & Johnson to Participate in the 39
th
Annual J.P. Morgan Healthcare Conference
See All News Releases
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
Johnson & Johnson To Appeal Flawed Opioid Judgment in Oklahoma
ON NOW
Webcast: Pharm Business Review 2019
Webcast: Pharm Business Review 2019
ON NOW
Webcast: Health for Humanity Report
Webcast: Health for Humanity Report
ON NOW
Statement on Reuters Talc Article
Statement on Reuters Talc Article
Johnson & Johnson issued the following statement regarding speculation about the safety of our products.
ON NOW
Investor Relations
Corporate Governance
Corporate Governance
ON NOW
SEC Filings
SEC Filings
ON NOW
Pharmaceutical Pipeline
Pharmaceutical Pipeline
ON NOW
Stock Information
Stock Information
ON NOW
Webcasts & Presentations
Webcasts & Presentations
ON NOW
Investor Fact Sheet
Investor Fact Sheet
ON NOW
Quarterly Results
See the latest quarterly sales and earnings from Johnson & Johnson, as well as historical results covering the past ten years.
Learn More
Shareholder Tools
Email Alerts Subscription
RSS News Feeds
Investor FAQs
Answers to common questions regarding purchasing and owning Johnson & Johnson stock.
Learn More
2019 Health for Humanity Report
We blend heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Learn More
Contact Investor Relations
Questions? Please contact Investor Relations:
1-800-950-5089
Learn more about our Guidelines for Communication with the Investment Community (Reg FD)
This site uses cookies as described in our
Cookie Policy
Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Accept